<DOC>
	<DOC>NCT00861016</DOC>
	<brief_summary>This is an open-label, non-comparative, multi-centre clinical study to evaluate the Efficacy and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with mild to moderate essential hypertension.</brief_summary>
	<brief_title>Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Felodipine</mesh_term>
	<criteria>Provision of written informed consent Newly diagnosed essential hypertension who have not received anti hypertensive treatment, or patients without antihypertensive medication in two weeks before screening, 90mmHg&lt;SiDBP &lt;110mmHg and SiSBP &lt;180mmHg. Known or suspected secondary hypertension Resting HR is &lt; 55bpm. Sick sinus syndrome Atrioventricular block of first degree (with PR&gt;0.24seconds), or second or third degree</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Post marketing study</keyword>
</DOC>